

PUBLICATIONS FROM MHF RESEARCH

2011

Abraham WT, Adamson PB, Bourge RC, Aaron MF, **Costanzo MR**, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavell D, Jefferies B, Yadav JA, for the CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet*. February 10, 2011. 9 pages

2010

Topor EJ, Bousser MG, Fox KAA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL, for the **CRESCENDO Investigators**: Rimonabant for the prevention of cardiovascular events (CRESCENDO): a randomised, multicenter, placebo-controlled trial. *Lancet*. 376:514-523, 2010

Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L, for the **CLOSURE I Investigators**: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale: *Stroke*. 41:2872-2883, 2010

O'Connor CM, Miller AB, Blair JEA, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M, for the **EVEREST investigators**: Causes of death and reshospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. *Am Heart J*. 159, 5:841-849, 2010

Rao SV, Melloni C, Meyles-DiMauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I, Roach J, Becker RC, **for the EMINENCE Investigators**: Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intervention (EMINENCE) Trial. *Circulation*. 121:1713-1721, 2010

Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Croke ST: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. *Lancet*. 375: 998-1006, 2010

2009

Weber MA, Black H, Bakria G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. *Lancet*. 374: 1423-1431, 2009

Moss, AJ, Hall, WJ, Cannon DS, Klein H, Brown MW, Daubert JP, Estes M, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, for the **MADIT-CRT Investigators**: Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. *N Eng J Med*. 361: 10 pages 1Sep2009

Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ, for the **ATHENA Investigators**. Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. *N Engl J Med*. 360:668-678, 2009

Gold, MR, Adler, S, Fauchier, L, Haffajee, C, Ip, J, Kainz, W, **Kawasaki, R**, Prakesh, A, Taborsky, M, Waller, T, Wilson, V, Li, S, Hoffman, E; Safari Investigators. Impact of atrial prevention pacing on atrial fibrillation burden: Primary results of the Study of Atrial Fibrillation Reduction. *Heart Rhythm*. 6 (3), 302-4.

2008

Blair JEA, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghide M, for the **EVEREST Investigators**: Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure. *J Am Coll Cardiol*. 52, 2:1640-1648, 2008

Chung ES, Leon AR, Tavazzi L, S, JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Y CM, Gorcsan J, Sutton MSJ, De Sutter J, Murillo J: Results of the Predictors of Response to CRT (PROSPECT) Trial. *Circulation*. 117: 2608-2616, 2008

Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R, for the **FUSION II Investigators**: Safety and Efficacy of Outpatient Nesiritide in Patients with Advanced Heart Failure: Results of the Second Follow-Up Serial Infusions of Nexirtide (Fusion II) Trial. *Circ Heart Failure*. 1:9-16, 2008

Pitt B, Loscalzo J, Yčas J, Raichlem JS: Lipid Levels After Coronary Syndromes. *J Am Coll Cardiol* 51, 15: 1440-1445, 2008

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenburg B, Krum H, Massie, BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, on behalf of the **STAMINA-HeFT Group**: Randomized Double-Blind Trial of Darbepoetin Alfa in Patients with Symptomatic Heart Failure and Anemia. *Circulation*. 117: 526-535, 2008

Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. *Diabetes, Obesity, and Metabolism*. 10:376-386, 2008

Jamerson J, Weber, MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, gupte J, Gatlin M, Velazquez EJ, for the **ACCOMPLISH trial investigators**: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. *N Engl J Med*. 359,23:2417-2428, 2008

Kereiakes DJ, Turco MA, Breall J, Farhat NZ, Feldman RL, McLaurin B, Popma JJ, Mauri L, Zimetbaum P, Massaro J, Cutlip DE, on behalf of the **AMETHYST Study Investigators**. A Novel Filter-Based Distal Embolic Protection Device for Percutaneous Intervention of Saphenous Vein Graft Lesions. *J Am Coll Cardiol Interv*. 1:248-257, 2008

Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moyé LA, Otterstand JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR, Young JB, for the **Advanced Chronic Heart Failure Clinical assessment of Immune Modulation Therapy Investigators**: Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. *Lancet*. 371:228-36, 2008

2007

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann, FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the **TRITON-TIMI 38 Investigators**: Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. *N Engl J Med*. 357, 20: 2001-2015, 2007

Hauptman PJ, Goodlin SJ, Lopatin M, **Costanzo MR**, Fonarow GC, Yancy CW, for the ADHERE Scientific Advisory Committee and ADHERE Study Group: *Arch Intern Med*. 167, 18: 1990-1997, 2007

Costanzo MR, Johannes RS, Pine M, Gupta V, **Saltzberg M**, Hay J, Yancy CW, Fonarow GC: The Safety of intravenous diuretics alone versus diuretics plus paraneural vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. *Am Ht J*. 154, 2: 267-277, 2007

Rao RK, Kumar UN, Schafer J, Esperanza V, De Lurgio D, Foster E: Reduced Ventricular Volumes and Improved Systolic Function with Cardiac Resynchronization Therapy- A Randomized Trial Comparing Simultaneous biventricular Pacing, Sequential Biventricular Pacing, and Left Ventricular Pacing. *Circulation*. 115:2136-2144, 2007.

Konstam MA, Gheorghide M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, for the **EVEREST Investigators**: Effects

of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. *JAMA*. 297, 12: 1319-1331, 2007

Gheorghiade M, Konstam M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannas F, Cook T, Ouyang J, Zimmer C, Orlandi C, for the **EVEREST Investigators**: Short-Term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials. *JAMA*. 297, 12:1332-1343, 2007

Costanzo MR, Guglin ME, **Saltzberg MT**, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA, for the UNLOAD Trial Investigators: Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure. *J Am Coll Cardiol* 49, 6: 675-83, 2007

The APEX AMI Investigators. Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. *JAMA*. 297,1:43-51, 2007

2006

Holmes, DR Jr., Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA, for the **SISR Investigators**: Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial. *JAMA*. 295, 11: 1264-1273, 2006

Gray WA, Hopkins LN, Yadav S, Davis T, Wholey M, Atkinson R, Cremonesi A, Fairman R, Walker G, Verta P, Popma J, Virmani R, Cohen DJ, for the **ARCHeR Trial Collaborators**. Protected carotid stenting in high-surgical risk patients: The ARCHeR results. *J Vasc Surg*. 44, 2:258-269, 2006

2005

Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P: Early Ultrafiltration in Patients With Decompensated Heart Failure and Diuretic Resistance. *JACC* 46, 11: 2047-2051, 2005

O'Toole MF, Kmetik KS, Bossley H, **Cahill JM**, Kotsos TP, **Schwamberger PA, Bufalino VJ**: Electronic Health Record Systems: The Vehicle for Implementing Performance Measures. *Am Heart Hosp J* 3: 88-93, 2005

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, for the **SCD-HeFT Investigators**: Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. *N Eng J Med* 352, 3: 225-237, 2005

2004

Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, **Saltzberg M**, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R: Primary Results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): A Multicenter Study of B-Type Natriuretic Peptide Levels, Emergency Department Decision Making, and Outcomes in Patients Presenting with Shortness of Breath. *JACC* 44, 6: 1328-1333, 2004

AFFIRM Investigators: Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. *Circulation*. 109:1509-1513, 2004

The SYNERGY Trial Investigators: Enoxaparin vs Unfractionated Heparin in High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Managed with an Intended Early Invasive Strategy. *JAMA* 292: 45-54, 2004

Yancy CW, **Saltzberg MT**, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA: Safety and Feasibility of Using Serial Infusions of Nesiritide for Heart Failure in an Outpatient Setting (from the FUSION I Trial). *Am J Cardiol* 94:595-601, 2004

Zimetbaum PJ, Buxton AE, Bastford W, Fisher JD, Hafley GE, Lee KL, **O'Toole MF**, Page RL, Reynolds M, Josephson ME: Electrocardiographic Predictors of Arrhythmic Death and Total Mortality in the Multicenter Unsustained Tachycardia Trial. *Circulation* 110:766-769, 2004.

Feldman T, Koren M, Insull W Jr., McKenney J, Schrott H, Lewin A, Shah S, Sidisin M, Cho M, Kush D, Mitchel Y: Treatment of High-Risk Patients with Ezetimibe Plus Simvastatin Co-Administration Versus Simvastatin Alone to Attain National Cholesterol Education Program Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals. *Am J Cardiol*. 93:1481-1486, 2004

2002

AFFIRM Investigators: Baseline characteristics of patients with atrial fibrillation: The AFFIRM study. *Am Heart J*. 143:991-1001, 2002

Kinn JW, Brown AS: Cardiovascular risk management in clinical practice. The Midwest Heart Specialists experience. *Am J Cardiol* 89 (Supple):23C-30C, 2002.

Caragher TE, Fernandez BB, Jacobs FL, **Barr LA:** Evaluation of quantitative cardiac biomarker point-of-care testing in the emergency department. *J Emerg Med* 22(1):1-7, 2002.

2001

Insull WJ, Koren M, Davignon J, Sprecher D, Schrott H, Keilson LM, **Brown AS**, et al: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. *Atherosclerosis* 157:137-144, 2001.

Kinn JW, O'Toole MF, Rowley SR, Marek JC, Bufalino VJ, Brown AS: Effectiveness of the electronic medical record in cholesterol management in patients with coronary artery disease (virtual lipid clinic). *Am J Cardiol*, 2001 88:163-165, 2001.

Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, **Barr L, et al**: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. *J Invas Cardiol* 13:272-278, 2001.

Lewis BE, **Wallis DE**, Berkowitz SD, et al: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. *Circulation* 103:1838-1843, 2001.

2000

Garmendia F, **Brown AS**, Reiber I, Adams PC: Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS Study). *Current Medical Research and Opinion* 16(3):208-219, 2000.

Caragher TE, Fernandez BA, **Barr LA**: Long-term experience with an accelerated protocol for diagnosis of chest pain. *Arch Pathol Lab Med* 124:1434-1439, 2000.

Kereiakes DJ, Fry E, Matthai W, Niederman A, **Barr L**, et al: Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". *J Invas Cardiol* 12 (Suppl A):1A-5A, 2000.

Brown AS, Cofer L: Lipid management in a private cardiology practice: The Midwest Heart experience. *Am J Cardiol* 85(2A):January 27, 2000.

1999

Rosen J, Tucheck JM, **Hartmann JR**: Liver laceration in the hemodynamically unstable post-cardiac massage patient: Early recognition and management - Case Report. *J Trauma: Injury, Infection, and Critical Care* 47(2):408-409, 1999.

Makkar R, Goff B, Eigler N, Sebastian M, Fischell T, **Barr L**, et al: Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI Pilot Study. *Catheterization Cardiovascular Interventions* 48:430-434, 1999.

Walenga JM, Lewis BE, Jeske WP, Leya F, **Wallis DE**, Bakhos M, Fareed J: Combined thrombin and platelet inhibition treatment for HIT patients. *Haemostaseologie* 19:128-13

Wallis DE, Lewis BE, Messmore HL, Pifarre R, Walenga JM: Inadequacy of current prevention strategies for heparin-induced thrombocytopenia. *Clin Appl Thrombosis/ Hemostasis* 5 (Suppl 1):S16-S20, 1999.

Wallis DE, Quintos R, Wehrmacher WH, Messmore H: Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. *Chest* 116:1333-1338, 1999.

Walenga JM, **Wallis DE**, Lewis BE, Leya F, Bakhos M, Fareed J: Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. *Seminars in Thrombosis and Hemostasis* 25(Suppl 1): 77-81, 1999.

Walenga J, Fasanella A, Iqbal O, Hoppensteadt DA, **Wallis DE**, Bakhos M: Coagulation laboratory testing in patients treated with argatroban. *Seminars in Thrombosis and Hemostasis* 25 (Suppl 1):61-66, 1999.

Brener SJ, **Barr, LA**, Burchenal JE, et al: Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. *Am J Cardiol* 84:728, 1999.

Makkar R, Goff B, Eigler N, Sebastian M, Fischell T, **Barr L**, et al: Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI Pilot Study. *Catheterization Cardiovascular Interventions* 48:430-434, 1999.

Rosen J, Tucheck JM, **Hartmann JR**: Liver laceration in the hemodynamically unstable post-cardiac massage patient: Early recognition and management - Case Report. *J Trauma: Injury, Infection, and Critical Care* 47(2):408-409, 1999.

Wallis DE, Lewis BE, Walenga J: Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: A clinician's perspective. *Seminars in Thrombosis and Hemostasis* 25(Suppl 1):3-7, 1999.

Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. *Am J Med* 106:629-635, 1999.

Anderson JL, Hallstrom AP, Epstein AE, Pinski SL, Rosenberg Y, **Nora, MO**, Chilson D, Cannom DS, Moore R, and the AVID Investigators: Design and results of the Antiarrhythmics vs Implantable Defibrillators (AVID) Registry. *Circulation* 99(13):1692-1699, 1999.

Rauh RA, **Schwabauer RJ**, **Enger EL**, Moran JF: A community hospital-based congestive heart failure program: Impact on length of stay, admission and readmission rates, and cost. *Am J Managed Care* 5(1):37, 1999.

Chamberlin JR, Lardi AB, **McKeever LS**, et al: Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro). *Cathet Cardiovasc Intervent* 47:143-147, 1999.

1998

Wallis DE, Lewis BE, Messmore H, Wehrmacher W: Heparin-induced thrombocytopenia and thrombosis syndrome. *Clinical and Applied Thrombosis/Hemostasis* (3):160-163, 1998.

Langholz D, Mackin WJ, **Wallis DW**, Jacobs WR, Scanlon PJ, Louie EK: Transesophageal echocardiographic assessment of systolic mitral leaflet displacement among patients with mitral valve prolapse. *Am Heart J* 135:197-206, 1998.

Brener SJ, **Barr LA**, Burchenal JEB, et al: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. *Circulation* 98:734-741, 1998.

Brown AS, Bakker-Arkema RG, Yellen L, et al: Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. *J Am Coll Cardiol* 32(3):665-672, 1998.

Kinn JW, Bache RJ: Effect of platelet activation on coronary collateral blood flow. *Circulation* 98(14):1431-7, 1998.

Traverse JH, **Kinn JW**, Klassen C, Duncker DJ, Bache RJ: Nitric oxide inhibition impairs blood flow during exercise in hearts with a collateral dependent myocardial region. *J Am Coll Cardiol* 31(1):67-74, 1998.

1997

Kinn JW, O'Neill WW, Benzuly KH, et al: Primary angioplasty reduces risk of myocardial rupture compared to thrombolytics in patients with acute myocardial infarction. *Cathet Cardiovasc Diagn*: 42(2):151-7, 1997.

The Coumadin Aspirin Reinfarction Study (CARS) Investigators (**Barr LA**): Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 350:389-396, 1997.

Lewis BE, Walenga JM, **Wallis DE**. Anticoagulation with Novastan® (Argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. *Seminars in Thrombosis and Hemostasis* 23:197-202, 1997.

1996

Louie EK, Langholz D, Mackin WJ, **Wallis DE**, Jacobs WR, Scanlon PJ. Transesophageal echocardiographic assessment of the contribution of intrinsic tissue thickness to the appearance of a thick mitral valve in patients with mitral valve prolapse. *J Am Coll Cardiol* 28:465-471, 1996.

Stephan WJ, O'Keefe JH Jr, Piehler JM, McCallister BD, Dahiya RS, Shimshak TM, Ligon RW, Hartzler GO: Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. *J Am Coll Cardiol* 28:1140-1146, 1996.

Hartmann JR, McKeever LS, O'Neill WW, White CJ, Whitlow PL, Gilmore PS, Doorey AJ, Galichia JP, **Enger EL**: Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts with longterm, low dose, direct infusion of urokinase: A serial trial (ROBUST) *J Am Coll Cardiol* 27:60-66, 1996.

1994

Weaver WD, **Hartmann JR**, Anderson J, Reddy PS: A new recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. *J Am Coll Cardiol* 24:1242-1248, 1994.

Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergran C, **Hartmann JR**, Talley JD, Frey MJ, Taylor G, Leimberger JD, Owens PM, Lee KL, Stack RS, Calliff RM: The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: Results of a randomized trial. *Circulation* 90:792-799, 1994.

Enger EL, Williamson JG: Polymorphonuclear induced oxidative burst in the MODS dog model. *Prostaglandins* 6:57-68, 1994.

1993

Waagstein F, Bristow M, Swedbert K, Camerini F, Folwer MB, Silver MA, Hjalmarson A: Beneficial effects metoprolol in idiopathic dilated cardiomyopathy (MDC) trial. A randomized controlled multicenter study. *Lancet* 342:1441-46, 1993.

O'Toole MF, Feldman T, Chiu YC, Carroll JD: Turbulence Intensity in Aortic Stenosis: Frequency Characteristics and Effects of Alterations in Left Ventricular Function. *J Heart Valve Dis* 2(1):94-102, 1993.

Kerwin PM, McKeever LS, Marek JC, Hartmann JR, Enger EL: Directional atherectomy of aorto-ostial lesions. *Catheterization Cardiovascular Diagnosis* 1:17-25, 1993.

McKeever LS, Marek JC, Kerwin PM, Cahill JM, Barr LA, Enger EL: Bail-out atherectomy for abrupt coronary artery occlusion following conventional angioplasty. *Catheterization Cardiovascular Diagnosis*, 1:31-36, 1993.

O'Toole MF, Feldman T, Chiu YC, Carroll JD: Turbulence intensity in aortic stenosis: Frequency characteristics and effects of alterations in left ventricular function. *J Heart Valve Dis* 2(1):94-102, 1993.

1992

Shirani J, Pick R, Guo Y, Silver MA: Usefulness of the electrocardiogram and echocardiogram in predicting the amount of interstitial myocardial collagen in endomyocardial biopsy specimens of patients with chronic heart failure. *Am J Cardiol* 69:1502-1503, 1992.

Stamato NJ, **O'Toole MF, Enger EL**: Permanent pacemaker implantation in the cardiac catheterization laboratory versus operating room: An analysis of hospital charges and complications. *PACE* 15:2236-2239, 1992.

Stamato NJ, **O'Toole MF**, Valguisti E, **Enger EL**: A technique utilizing a steerable hydrophilic guidewire for permanent pacemaker implantation. *PACE* 15:1244-1247, 1992.

Stamato NJ, **O'Toole MF**, Fetter JG, **Enger EL**: The safety and efficacy of chronic ventricular pacing at 1.6 volts using a steroid eluting lead. *PACE* 15:248-251, 1992.

1991

McKeever LS, O'Donnell MJ, Stamato NJ, **Cahill JM, Hartmann JR, Marek JC, Brown AS, Enger EL**: The effect of predilatation on angioplasty induced vessel wall injury. *Am Heart J* 122:1515-1518, 1991.

Hartmann JR, McKeever LS, Stamato NJ, **Bufalino VJ, Marek JC, Brown AS, Goodwin MJ, Cahill JM, Enger EL**: Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts by extended infusion of urokinase. Initial results and one year follow-up. *J Am Coll Cardiol* 18(6):1517-1523, 1991.

1990

Gottlieb CD, Rosenthal ME, Stamato NJ, Frame LH, Lesh MD, Miller JM, Josephson ME: A quantitative evaluation of refractoriness within a reentrant circuit during ventricular tachycardia. *Circulation* 82:1289-1295, 1990.

Hartmann JR, McKeever LS, Bufalino VJ, Marek JC, Brown AS, Goodwin MJ, Colandrea MA, Stamato NJ, **Cahill JM**, O'Donnell MJ, Amirparviz F, Enger EL: A randomized trial of intravenous streptokinase versus tissue plasminogen activator for the treatment of acute myocardial infarction: Results using an aggressive approach. *J Intervent Cardiol* 3(2):69-73, 1990.

Bluemel KM, **O'Toole MF**, Randall WC, Wurster RD: Vagal postganglionic pathways to the sinoatrial node of the canine heart. *Am J Physiol* 259(5 Pt 2):H1504-10, 1990.

Teplinsky K, **O'Toole M**, Olman M, Walley K, Wood LDH: Effect of lactic acidosis on canine hemodynamics and cardiac function. *Am J Physiol* 248(4 Pt 2):H1193-9, 1990.

1989

Stamato NJ, **Goodwin MJ**, Foy B: Diagnosis of coronary sinus diverticulum in Wolff-Parkinson-White Syndrome using coronary angiography. *PACE* 12:1589-1591, 1989.

Stamato NJ, **Cahill JM**, **Goodwin MJ**, Winters G: Cardiac amyloidosis causing ventricular tachycardia: Diagnosis made by endomyocardial biopsy. *Chest* 96(6):1431-1433, 1989.

Stamato NJ, Frame LH, Rosenthal ME, Almendral JM, Gottlieb CD, Josephson ME: Procainamide-induced slowing of ventricular tachycardia with insights from analysis of resetting response patterns. *Am J Cardiol* 63:1455-1461, 1989.

Goodwin MJ, **Hartmann JR**, **McKeever LS**, **Bufalino VJ**, **Marek JC**, **Brown AS**, Colandrea MA, Stamato NJ, **Cahill JM**, O'Donnell MJ, Amirparviz F, **Enger EL**: Safety of intraaortic balloon counterpulsation in patients with acute myocardial infarction receiving streptokinase intravenously. *Am J Cardiol* 64:937-938, 1989.

McKeever LS, **Hartmann JR**, **Bufalino VJ**, **Marek JC**, **Brown AS**, **Goodwin MJ**, Colandrea MA, Stamato NJ, **Cahill JM**, O'Donnell MJ, Amirparviz F, **Enger EL**: Acute myocardial infarction complicating recanalization of aortocoronary bypass grafts with urokinase therapy. *Am J Cardiol* 64:683-685, 1989.

1988

Hartmann JR, **McKeever LS**, **Bufalino VJ**, **Marek JC**, **Brown AS**, **Goodwin MJ**, Colandrea MA, Stamato NJ, **Cahill JM**, Amirparviz F: A system approach to intravenous thrombolysis in acute myocardial infarction in community hospitals. The influence of paramedics. *Clin Cardiol* 11:812-816, 1988.

Hartmann J, McKeever L, Teran J, Bufalino V, Marek J, Brown A, Goodwin M, Amirparviz F, Motarjeme A: Prolonged infusion of urokinase for recanalization of chronically occluded aortocoronary bypass grafts. *Am J Cardiol* 61(1):189-191, 1988.

1986

Hartmann JR, **McKeever LS**, **Bufalino VJ**, Amirparviz F, Scanlon PJ: Intravenous streptokinase in acute myocardial infarction: Experience of community hospitals serviced by paramedics. *Am Heart J* 3(6):1030-1034, 1986.